Sirius Therapeutics to Present Data from its Phase 1 Clinical Trial of Factor XI siRNA, a Next-Generation Long-Acting Anticoagulant for Thromboembolic Disease, at the 66th Annual ASH Meeting and Exposition
https://t.co/jwhMUX8Pd7
The US FDA approves AOP Health’s Rapiblyk TM (landiolol) for the treatment of atrial fibrillation and atrial flutter in critical care
https://t.co/VPcpRLkiT8
ASML INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ASML Holding NV Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
https://t.co/DzELqkw7FS
ATTENTION – CORRECTION: Here is the corrected dispatch: Altasciences supports Metsera in its preliminary clinical trials on obesity
https://t.co/t8fTZiLhsR
ASML HOLDING SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ASML Holding N.V. – ASML
https://t.co/ymqIVSMoRK
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
https://t.co/sbttvFvZyD
Rosen Law Firm Urges ASML Holding N.V. (NASDAQ: ASML) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
https://t.co/wXfOBSXB3S